{
    "organizations": [],
    "uuid": "c9b35c8e2e0a8b1b7045edcd44c7e79bc7988b3d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gw-pharmaceuticals-receives-orphan/brief-gw-pharmaceuticals-receives-orphan-drug-designation-from-ema-for-cannabidiol-for-the-treatment-of-tuberous-sclerosis-idUSFWN1QH0OJ",
    "ord_in_thread": 0,
    "title": "BRIEF-GW Pharmaceuticals Receives Orphan Drug Designation From EMA For Cannabidiol For The Treatment Of Tuberous Sclerosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - GW Pharmaceuticals Plc:\n* GW PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CANNABIDIOL FOR THE TREATMENT OF TUBEROUS SCLEROSIS\n* GW PHARMACEUTICALS PLC - SUBJECT TO POSITIVE RESULTS, GW EXPECTS TO SUBMIT REGULATORY APPLICATIONS IN 2019 FOR EPIDIOLEX IN TS IN BOTH U.S. AND EUROPE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T20:09:00.000+02:00",
    "crawled": "2018-02-27T14:11:58.073+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "gw",
        "pharmaceutical",
        "plc",
        "gw",
        "pharmaceutical",
        "receives",
        "orphan",
        "drug",
        "designation",
        "european",
        "medicine",
        "agency",
        "ema",
        "cannabidiol",
        "treatment",
        "tuberous",
        "sclerosis",
        "gw",
        "pharmaceutical",
        "plc",
        "subject",
        "positive",
        "result",
        "gw",
        "expects",
        "submit",
        "regulatory",
        "application",
        "epidiolex",
        "t",
        "europe",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}